A single-dose mRNA vaccine induces potent and long-lasting humoral and cellular immunity against the varicella-zoster virus in a murine model - PubMed
6 hours ago
- #varicella-zoster virus
- #mRNA vaccine
- #immunogenicity
- A novel mRNA vaccine candidate, KH014, targeting varicella-zoster virus (VZV) glycoprotein E, was developed using ionizable lipid nanoparticles.
- In mouse studies, a single dose of KH014 induced stronger and longer-lasting humoral and cellular immune responses compared to the licensed vaccine Shingrix®.
- KH014 elicited persistent CD4+ T-cell responses for at least 10 weeks, with heterologous prime-boost regimens further enhancing polyfunctional T-cell and memory profiles.
- The findings support KH014 as a potential single-dose vaccine for herpes zoster, with implications for optimizing immunization strategies.
- The study was funded and conducted by Chengdu Kanghua Biological Products Co., Ltd., with all authors employed by the company.